同行评审出版物

投资者关系

投资者信息中心

公告与通函

投资者演示文稿

投资者关系联系方式

投资者关系日历

发布公司通讯

关于CQ9电子

战略顾问委员会

高级科学顾问委员会

科学研发

> 同行评审出版物

同行评审出版物

同行评审出版物

Diabetes, Obesity and Metabolism

Diabetes remission in drug-naïve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study

Diabetes Therapy

Time in Range Estimation in Patients with Type 2 Diabetes is Improved by Incorporating Fasting and Postprandial Glucose Levels

Nature Communications

2023 March, Nature Communications: A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity

Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes

Nature Medicine

2022 May, Nature Medicine Comments: A new class of drug in the diabetes toolbox.

Nature Medicine

2022 May, Nature Medicine: Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

Nature Medicine

2022 May, Nature Medicine: Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

Clinical and Translational Science

2021 August, Clinical and Translational Science: Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual-acting glucokinase activator.

Global Journal of Obesity, Diabetes and Metabolic Syndrome

2020 June / Meta-analysis of the epidemiology of microvascular complications in people with Type 2 diabetes in mainland China

Diabetes, Obesity and Metabolism

2018 February / Diabetes, Obesity and Metabolism: Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection

Clinical Pharmacokinetics

2018 April / Clinical Pharmacokinetics: Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration–Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics

Lancet Diabetes Endocrinology

2018 MAY / Lancet Diabetes Endocrinology: New hope for glucokinase activators in type 2 diabetes?

Lancet Diabetes Endocrinology

2018 May / Lancet Diabetes Endocrinology: Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study

Journal of Diabetes Research

2017 January / Journal of Diabetes Research: Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus

2016年第3期《药学进展》：葡萄糖激酶激活剂研究进展

2016年第3期《药学进展》：21世纪2型糖尿病新药研发策略：明鉴病理因素，改善机体功能

Drug Design, Development and Therapy

2016 May / Drug Design, Development and Therapy: Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study

Intractable & Rare Diseases Research

2016 October / Intractable & Rare Diseases Research: Orphan drug development in China ‒ Turning challenges into opportunities

Clinical Pharmacokinetics

2016 December / Clinical Pharmacokinetics: Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn–Research–Confirm Process

Intractable & Rare Diseases Research

2015 / Intractable & Rare Diseases Research：Fragile X syndrome as a rare disease in China – Therapeutic challenges and opportunities

关注我们

Copyright © 2024 CQ9电子医药技术（上海）有限公司互联网药品信息服务资格证书编号: （沪）-非经营-2022-0079
沪ICP备92345701号-1

沪公网安备 31011502013809号隐私声明使用条款

搜索

我们如何使用Cookies

CQ9电子医药使用 Cookie 来改进网站的使用。继续使用本网站即表示您同意使用这些 Cookie。如需了解更多关于 Cookie 的信息，请阅读我们的隐私声明。

全部接受

x

网站首页 CQ9电子